<DOC>
	<DOCNO>NCT01393145</DOCNO>
	<brief_summary>A study multicenter , phase III , randomize , open label study evaluate efficacy safety fixed-dose combination formoterol/fluticasone salmeterol/fluticasone patient moderate-to-severe chronic obstructive pulmonary disease ( COPD ) enroll 336 subject age ≥ 40 year , smoker former smoker , diagnose chronic obstructive pulmonary disease , classify moderate chronic obstructive pulmonary disease severe accord GOLD spirometric classification . The subject allocate 2 parallel group receive medicine study , accord randomization 24-week .</brief_summary>
	<brief_title>Efficacy Safety Study Formoterol/Fluticasone Salmeterol/Fluticasone Patients With Moderate-to-severe COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>1 . Age ≥ 40 year ; 2 . Chronic obstructive pulmonary disease classify moderate severe accord GOLD guideline ( Global Initiative Chronic Obstructive Lung Disease ) , postbronchodilator FEV1/FVC &lt; 0.70 , postbronchodilator FEV1 &lt; 80 % ≥ 30 % predict ; 3 . Understanding capacity give write consent ; 4 . Smoker exsmoker ≥ 10 packyears [ number packyears = number daily cigarettes / 20 x number year smoke ( eg t10 packyears equal 20 cigarette / day 10 year , 10 cigarette per day within 20 year ) ] . 5 . Ability fill patient 's Diary 6 . Ability fill MRC dyspnea scale questionnaire CAT CDLM . 1 . Presence clinically associate morbidity manifest accord investigator would interfere evaluation , example : diabetes mellitus , congestive heart failure , coronary heart disease , chronic renal failure , liver failure , arrhythmia , hypothyroidism hyperthyroidism ; 2 . Presence neuropsychiatric disorder kind ; 3 . Presence mental retardation etiology ; 4 . Presence pulmonary malformation , bronchiectasis , cystic fibrosis , bronchopulmonary hemosiderosis , ciliary dyskinesia , alveolitis , hypersensitivity , pulmonary vasculitis , sarcoidosis , tuberculosis lung disease might interfere study assessment , investigator 's discretion ; 5 . Subjects use immunosuppressive therapy , immunomodulatory agent , chemotherapy allergy immunotherapy ; 6 . Subjects use xanthine acebrophylline ; 7 . Use within two month precede screen visit ( V2 ) : antileukotrienes , immunoglobulin ( include omalizumab ) , beta blocker , digitalis , itraconazole , amiodarone , antidepressant , monoamine oxidase inhibitor , tricyclic antidepressant , rifampin , oral contraceptive coumarin ; 8 . Current diagnosis asthma ; 9 . Symptomatic coronary insufficiency ; 10 . Surgery lung volume reduction / lung transplantation ; 11 . Need longterm oxygen therapy ( define need oxygen therapy ≥ 12 hour / day ) ; 12 . Pregnant test βHCG serum positive ; 13 . Lactating woman ; 14 . Subject use 2 alcohol drink day &gt; 14 drink week ; 15 . Subject history malignancy ≤ 5 year &gt; 5 year , without documentation remission / cure . 16 . Illiterate individual limitation understanding use device well inability understand questionnaire diary apply ; Exception : subject illiterate , capable understand regard use device , questionnaires diary study make available relative fill diary study . 17 . History hypersensitivity study drug rescue ; 18 . Any disease therapy opinion investigator would jeopardize subject interfere objective study ; 19 . Subject history ineffectiveness formoterol fumarate , fluticasone salmeterol xinafoate ; 20 . Subject participate another study within 1 ( one ) year ; 21 . Pregnant woman positive serum βHCG ; 22 . Radiological change compatible COPD ; 23 . Clinically significant ECG change , report investigator ; 24 . Any disease , therapy laboratory abnormality opinion investigator would jeopardize subject interfere objective study ; 25 . Use medication prescribe exclusion criterion visit V 2 . 26 . Subjects exacerbation standardization require systemic corticosteroid / antibiotic hospitalization eligible randomization . 27 . Use oral corticosteroid , antileukotrienes , immunoglobulin ( include omalizumab ) , beta blocker , digitalis , amiodarone , itraconazole , antidepressant , monoamine oxidase inhibitor tricyclic antidepressant period standardization ; 28 . Any disease therapy opinion investigator would jeopardize subject interfere objective study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic obstructive pulmonary disease ( COPD )</keyword>
	<keyword>salmeterol</keyword>
	<keyword>fluticasone</keyword>
	<keyword>formoterol</keyword>
	<keyword>FEV1</keyword>
	<keyword>Moderate-to-severe</keyword>
</DOC>